<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21795339</PMID><DateCompleted><Year>2011</Year><Month>10</Month><Day>31</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>85</Volume><Issue>19</Issue><PubDate><Year>2011</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J Virol</ISOAbbreviation></Journal><ArticleTitle>Enterovirus 71 and coxsackievirus A16 3C proteases: binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design.</ArticleTitle><Pagination><StartPage>10319</StartPage><EndPage>10331</EndPage><MedlinePgn>10319-31</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.00787-11</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV71) and coxsackievirus A16 (CVA16) are the major causative agents of hand, foot, and mouth disease (HFMD), which is prevalent in Asia. Thus far, there are no prophylactic or therapeutic measures against HFMD. The 3C proteases from EV71 and CVA16 play important roles in viral replication and are therefore ideal drug targets. By using biochemical, mutational, and structural approaches, we broadly characterized both proteases. A series of high-resolution structures of the free or substrate-bound enzymes were solved. These structures, together with our cleavage specificity assay, well explain the marked substrate preferences of both proteases for particular P4, P1, and P1' residue types, as well as the relative malleability of the P2 amino acid. More importantly, the complex structures of EV71 and CVA16 3Cs with rupintrivir, a specific human rhinovirus (HRV) 3C protease inhibitor, were solved. These structures reveal a half-closed S2 subsite and a size-reduced S1' subsite that limit the access of the P1' group of rupintrivir to both enzymes, explaining the reported low inhibition activity of the compound toward EV71 and CVA16. In conclusion, the detailed characterization of both proteases in this study could direct us to a proposal for rational design of EV71/CVA16 3C inhibitors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Guangwen</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Chinese Academy of Sciences, Beijing 100101, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qi</LastName><ForeName>Jianxun</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Zhujun</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Xiang</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Feng</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Daizong</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Wangke</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Hong</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Hualiang</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Jinghua</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>George F</ForeName><Initials>GF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>07</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007555">Isoxazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011760">Pyrrolidinones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>47E5O17Y3R</RegistryNumber><NameOfSubstance UI="D010649">Phenylalanine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D003546">Cysteine Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.28</RegistryNumber><NameOfSubstance UI="D000086042">3C Viral Proteases</NameOfSubstance></Chemical><Chemical><RegistryNumber>HG18B9YRS7</RegistryNumber><NameOfSubstance UI="D014633">Valine</NameOfSubstance></Chemical><Chemical><RegistryNumber>RGE5K1Q5QW</RegistryNumber><NameOfSubstance UI="C118874">rupintrivir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086042" MajorTopicYN="N">3C Viral Proteases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018360" MajorTopicYN="N">Crystallography, X-Ray</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003546" MajorTopicYN="N">Cysteine Endopeptidases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015195" MajorTopicYN="N">Drug Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007555" MajorTopicYN="N">Isoxazoles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010649" MajorTopicYN="N">Phenylalanine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011760" MajorTopicYN="N">Pyrrolidinones</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014633" MajorTopicYN="N">Valine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>11</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21795339</ArticleId><ArticleId IdType="pmc">PMC3196414</ArticleId><ArticleId IdType="doi">10.1128/JVI.00787-11</ArticleId><ArticleId IdType="pii">JVI.00787-11</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adams P. D., et al. 2010. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66:213&#x2013;221</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2815670</ArticleId><ArticleId IdType="pubmed">20124702</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander J. P., Jr., Baden L., Pallansch M. A., Anderson L. J. 1994. Enterovirus 71 infections and neurologic disease&#x2014;United States, 1977&#x2013;1991. J. Infect. Dis. 169:905&#x2013;908</Citation><ArticleIdList><ArticleId IdType="pubmed">8133108</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand K., et al. 2002. Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain. EMBO J. 21:3213&#x2013;3224</Citation><ArticleIdList><ArticleId IdType="pmc">PMC126080</ArticleId><ArticleId IdType="pubmed">12093723</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger A., Schechter I. 1970. Mapping the active site of papain with the aid of peptide substrates and inhibitors. Phil. Trans. R. Soc. Lond. B Biol. Sci. 257:249&#x2013;264</Citation><ArticleIdList><ArticleId IdType="pubmed">4399049</ArticleId></ArticleIdList></Reference><Reference><Citation>Bible J. M., et al. 2008. Molecular epidemiology of human enterovirus 71 in the United Kingdom from 1998 to 2006. J. Clin. Microbiol. 46:3192&#x2013;3200</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2566106</ArticleId><ArticleId IdType="pubmed">18650362</ArticleId></ArticleIdList></Reference><Reference><Citation>Binford S. L., et al. 2005. Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor. Antimicrob. Agents Chemother. 49:619&#x2013;626</Citation><ArticleIdList><ArticleId IdType="pmc">PMC547258</ArticleId><ArticleId IdType="pubmed">15673742</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan K. P., et al. 2003. Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg. Infect. Dis. 9:78&#x2013;85</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2873753</ArticleId><ArticleId IdType="pubmed">12533285</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K. T., Chang H. L., Wang S. T., Cheng Y. T., Yang J. Y. 2007. Epidemiologic features of hand-foot-mouth disease and herpangina caused by enterovirus 71 in Taiwan, 1998&#x2013;2005. Pediatrics 120:e244&#x2013;e252</Citation><ArticleIdList><ArticleId IdType="pubmed">17671037</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S. C., Chang H. L., Yan T. R., Cheng Y. T., Chen K. T. 2007. An eight-year study of epidemiologic features of enterovirus 71 infection in Taiwan. Am. J. Trop. Med. Hyg. 77:188&#x2013;191</Citation><ArticleIdList><ArticleId IdType="pubmed">17620652</ArticleId></ArticleIdList></Reference><Reference><Citation>Chua K. B., et al. 2007. Genetic diversity of enterovirus 71 isolated from cases of hand, foot and mouth disease in the 1997, 2000 and 2005 outbreaks, Peninsular Malaysia. Malays. J. Pathol. 29:69&#x2013;78</Citation><ArticleIdList><ArticleId IdType="pubmed">19108398</ArticleId></ArticleIdList></Reference><Reference><Citation>Collaborative Computing Project Number 4 1994. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50:760&#x2013;763</Citation><ArticleIdList><ArticleId IdType="pubmed">15299374</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui S., et al. 2011. Crystal structure of human enterovirus 71 3C protease. J. Mol. Biol. 408:449&#x2013;461</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7094522</ArticleId><ArticleId IdType="pubmed">21396941</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P., Cowtan K. 2004. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60:2126&#x2013;2132</Citation><ArticleIdList><ArticleId IdType="pubmed">15572765</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert G. L., et al. 1988. Outbreak of enterovirus 71 infection in Victoria, Australia, with a high incidence of neurologic involvement. Pediatr. Infect. Dis. J. 7:484&#x2013;488</Citation><ArticleIdList><ArticleId IdType="pubmed">2841639</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouet P., Courcelle E., Stuart D. I., Metoz F. 1999. ESPript: analysis of multiple sequence alignments in PostScript. Bioinformatics 15:305&#x2013;308</Citation><ArticleIdList><ArticleId IdType="pubmed">10320398</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M., et al. 1999. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N. Engl. J. Med. 341:929&#x2013;935</Citation><ArticleIdList><ArticleId IdType="pubmed">10498487</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishimaru Y., Nakano S., Yamaoka K., Takami S. 1980. Outbreaks of hand, foot, and mouth disease by enterovirus 71. High incidence of complication disorders of central nervous system. Arch. Dis. Child. 55:583&#x2013;588</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1627055</ArticleId><ArticleId IdType="pubmed">6254449</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo C. J., et al. 2008. Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents. Bioorg. Med. Chem. 16:7388&#x2013;7398</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7125518</ArticleId><ArticleId IdType="pubmed">18583140</ArticleId></ArticleIdList></Reference><Reference><Citation>Laskowski R. A., Macarthur M. W., Moss D. S., Thornton J. M. 1993. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26:283&#x2013;291</Citation></Reference><Reference><Citation>Lee C. C., et al. 2009. Structural basis of inhibition specificities of 3C and 3C-like proteases by zinc-coordinating and peptidomimetic compounds. J. Biol. Chem. 284:7646&#x2013;7655</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2658058</ArticleId><ArticleId IdType="pubmed">19144641</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J. C., et al. 2008. A mammalian cell-based reverse two-hybrid system for functional analysis of 3C viral protease of human enterovirus 71. Anal. Biochem. 375:115&#x2013;123</Citation><ArticleIdList><ArticleId IdType="pubmed">18190777</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei X., et al. 2010. The 3C protein of enterovirus 71 inhibits retinoid acid-inducible gene I-mediated interferon regulatory factor 3 activation and type I interferon responses. J. Virol. 84:8051&#x2013;8061</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2916543</ArticleId><ArticleId IdType="pubmed">20519382</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews D. A., et al. 1999. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc. Natl. Acad. Sci. U. S. A. 96:11000&#x2013;11007</Citation><ArticleIdList><ArticleId IdType="pmc">PMC34232</ArticleId><ArticleId IdType="pubmed">10500114</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosimann S. C., Cherney M. M., Sia S., Plotch S., James M. N. 1997. Refined X-ray crystallographic structure of the poliovirus 3C gene product. J. Mol. Biol. 273:1032&#x2013;1047</Citation><ArticleIdList><ArticleId IdType="pubmed">9367789</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberste M. S., Penaranda S., Maher K., Pallansch M. A. 2004. Complete genome sequences of all members of the species Human enterovirus A. J. Gen. Virol. 85:1597&#x2013;1607</Citation><ArticleIdList><ArticleId IdType="pubmed">15166444</ArticleId></ArticleIdList></Reference><Reference><Citation>Otwinowski Z., Minor W. 1997. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276:307&#x2013;326</Citation><ArticleIdList><ArticleId IdType="pubmed">27754618</ArticleId></ArticleIdList></Reference><Reference><Citation>Patick A. K., et al. 1999. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob. Agents Chemother. 43:2444&#x2013;2450</Citation><ArticleIdList><ArticleId IdType="pmc">PMC89498</ArticleId><ArticleId IdType="pubmed">10508022</ArticleId></ArticleIdList></Reference><Reference><Citation>Phan J., et al. 2002. Structural basis for the substrate specificity of tobacco etch virus protease. J. Biol. Chem. 277:50564&#x2013;50572</Citation><ArticleIdList><ArticleId IdType="pubmed">12377789</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu J. 2008. Enterovirus 71 infection: a new threat to global public health? Lancet Neurol. 7:868&#x2013;869</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7128195</ArticleId><ArticleId IdType="pubmed">18848307</ArticleId></ArticleIdList></Reference><Reference><Citation>Racaniello V. R. 2007. Picornaviridae: the viruses and their replication, 796&#x2013;839 In Knipe D. M., et al. (ed.), Fields virology, 5th ed. Lippincott Williams &amp; Wilkins, Philadelphia, PA</Citation></Reference><Reference><Citation>Robinson C. R., Doane F. W., Rhodes A. J. 1958. Report of an outbreak of febrile illness with pharyngeal lesions and exanthem: Toronto, summer 1957; isolation of group A Coxsackie virus. Can. Med. Assoc. J. 79:615&#x2013;621</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1830188</ArticleId><ArticleId IdType="pubmed">13585281</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih S. R., et al. 2004. Mutations at KFRDI and VGK domains of enterovirus 71 3C protease affect its RNA binding and proteolytic activities. J. Biomed. Sci. 11:239&#x2013;248</Citation><ArticleIdList><ArticleId IdType="pubmed">14966374</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu H., et al. 2004. Molecular epidemiology of enterovirus 71 infection in the Western Pacific Region. Pediatr. Int. 46:231&#x2013;235</Citation><ArticleIdList><ArticleId IdType="pubmed">15056257</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeney T. R., Roque-Rosell N., Birtley J. R., Leatherbarrow R. J., Curry S. 2007. Structural and mutagenic analysis of foot-and-mouth disease virus 3C protease reveals the role of the beta-ribbon in proteolysis. J. Virol. 81:115&#x2013;124</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1797255</ArticleId><ArticleId IdType="pubmed">17065215</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian X., et al. 2009. Structure and cleavage specificity of the chymotrypsin-like serine protease (3CLSP/nsp4) of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). J. Mol. Biol. 392:977&#x2013;993</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7094510</ArticleId><ArticleId IdType="pubmed">19646449</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai M. T., et al. 2009. Real-time monitoring of human enterovirus (HEV)-infected cells and anti-HEV 3C protease potency by fluorescence resonance energy transfer. Antimicrob. Agents Chemother. 53:748&#x2013;755</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2630644</ArticleId><ArticleId IdType="pubmed">19015331</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng K. F., Li M. L., Hung C. T., Shih S. R. 2009. Enterovirus 71 3C protease cleaves a novel target CstF-64 and inhibits cellular polyadenylation. PLoS Pathog. 5:e1000593.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2742901</ArticleId><ArticleId IdType="pubmed">19779565</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong K. T., et al. 2008. The distribution of inflammation and virus in human enterovirus 71 encephalomyelitis suggests possible viral spread by neural pathways. J. Neuropathol. Exp. Neurol. 67:162&#x2013;169</Citation><ArticleIdList><ArticleId IdType="pubmed">18219253</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y., et al. 2010. Structures of EV71 RNA-dependent RNA polymerase in complex with substrate and analogue provide a drug target against the hand-foot-and-mouth disease pandemic in China. Protein Cell 1:491&#x2013;500</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4875138</ArticleId><ArticleId IdType="pubmed">21203964</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y., et al. 2010. The largest outbreak of hand, foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus A strains. Int. J. Infect. Dis. 14:e1076&#x2013;e1081</Citation><ArticleIdList><ArticleId IdType="pubmed">20952237</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F., et al. 2009. Enterovirus 71 outbreak in the People's Republic of China in 2008. J. Clin. Microbiol. 47:2351&#x2013;2352</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2708525</ArticleId><ArticleId IdType="pubmed">19439545</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H., et al. 2003. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc. Natl. Acad. Sci. U. S. A. 100:13190&#x2013;13195</Citation><ArticleIdList><ArticleId IdType="pmc">PMC263746</ArticleId><ArticleId IdType="pubmed">14585926</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D., Lu J. 2010. Enterovirus 71 vaccine: close but still far. Int. J. Infect. Dis. 14:e739&#x2013;e743</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7110504</ArticleId><ArticleId IdType="pubmed">20400350</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., et al. 2010. Molecular evidence of persistent epidemic and evolution of subgenotype B1 coxsackievirus A16-associated hand, foot, and mouth disease in China. J. Clin. Microbiol. 48:619&#x2013;622</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2815627</ArticleId><ArticleId IdType="pubmed">20018819</ArticleId></ArticleIdList></Reference><Reference><Citation>Zunszain P. A., et al. 2010. Insights into cleavage specificity from the crystal structure of foot-and-mouth disease virus 3C protease complexed with a peptide substrate. J. Mol. Biol. 395:375&#x2013;389</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7099390</ArticleId><ArticleId IdType="pubmed">19883658</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>